Navigation Links
Hypertension Diagnostics Announces Fiscal Year 2007 Results
Date:9/27/2007

ST. PAUL, Minn., Sept. 27 /PRNewswire-FirstCall/ -- Hypertension Diagnostics, Inc. (OTC Bulletin Board: HDII), today announced audited financial results for the fiscal year ended June 30, 2007.

Revenue for fiscal year 2007 totaled $1,878,840 compared to $1,789,546 in the prior year ended June 30, 2006, which represents a 5% increase. The Company incurred a net loss of $504,011 for fiscal year 2007, or $(.01) per share, compared with a net loss of $1,272,742 for fiscal year 2006, or $(.04) per share. Included in the net loss for fiscal year 2007 are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of $290,989. The Company reported a cash balance on June 30, 2007 of $1,376,632.

Fourth quarter revenue of $438,481, for fiscal year 2007 compared to $295,536 for fiscal year 2006, represented a 48% increase. Revenue for the fourth quarter of fiscal year 2007 decreased by 6.5% compared with $469,151 for the third quarter of fiscal year 2007.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2006 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

Hypertension Diagnostics, Inc.

Summary Financial Data

Statements of Operations

Three Months Ended Twelve Months Ended

June 30 June 30

2007 2006 2007 2006

Revenue:

Equipment sales $ 379,100 $ 209,500 $ 1,593,706 $ 1,352,486

Equipment rental 56,707 84,769 255,247 418,979

Service/contract

income 2,674 1,267 29,887 18,081

438,481 295,536 1,878,840 1,789,546

Cost of Sales 18,939 1,483 66,413 90,447

Gross Profit 419,542 294,053 1,812,427 1,699,099

Expenses:

Selling, general

and administrative 447,678 685,958 2,381,310 3,018,624

Total Expenses 447,678 685,958 2,381,310 3,018,624

Operating Loss (28,136) (391,905) (568,883) (1,319,525)

Other Income:

Interest income 14,558 16,338 56,773 46,783

Gain on sale of

property and

equipment - - 8,099 -

Total Other

Income 14,558 16,338 64,872 46,783

Net Loss $ (13,578) $ (375,567) $ (504,011) $(1,272,742)

Basic and Diluted

Net Loss

per Share $ (.00) $ (.01) $ (.01) $ (.04)

Weighted Average

Shares

Outstanding 39,620,262 39,714,469 39,793,320 35,219,474

Balance Sheet Data

June 30, 2007 June 30, 2006

Cash and cash

equivalents $ 1,376,632 $ 1,722,913

Total current assets 1,976,825 2,257,390

Total assets 2,020,385 2,345,949

Total current liabilities 582,124 489,081

Accumulated deficit (26,482,330) (25,978,319)

Total shareholders' equity 1,426,143 1,840,414

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: http://www.hdii.com


'/>"/>
SOURCE Hypertension Diagnostics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. New viewpoint on Hypertension
3. Hypertension drugs could lower Disability
4. Preventing white coat hypertension
5. New drug for hypertension
6. FDA Approves Remodulin for Pulmonary Hypertension
7. Risk of dementia reduced hypertension drugs
8. Glaucoma & Ocular Hypertension more likely in patients with refractive errors
9. Hypertension lowered by Bedtime Dosing
10. An hour of exercise a week cuts hypertension
11. Better Treatment For Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: